Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Resectable Head and Neck and Non-small Cell Lung Cancer
2024-516189-12-00Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxychloroquine in head and neck squamous cell carcinoma (HNSCC), Pulmonary squamous cell carcinoma and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 cohorts), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Biological effect of hydroxychloroquine on autophagic and immunological markers. Started Jul 2024; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Pulmonary squamous cell carcinomaNon-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2024-516189-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516189-12-00.